CREO
NEUTRALCreo Medical Appoints Deutsche Bank as New Nominated Adviser
The medical device company has appointed Deutsche Bank AG, London Branch as its new Nominated Adviser and Broker, replacing Numis Securities Limited.
Creo Medical Group
13.25GBX
-0.93%
Market Cap
56.19M
Volume
450.85k
24% of avg
P/E Ratio
-0.04
EPS (TTM)
-2.95
Beta
0.55
Day Range
13.00p - 13.50p
52 Week Range
0.09p13.25p37.00p
13.25p
Upcoming Events
May 2026
Expected release of FY2025 financial results
High Impact Event
CREO
NEUTRALCreo Medical Provides AGM Update, Announces Board Changes
The medical device company provides an update ahead of its AGM, announcing board changes and highlighting progress in its core technology and product pipeline.
CREO
NEUTRALCreo Medical Receives FDA Clearance for SpydrBlade™ Flex Device
The medical device company has received FDA clearance for its new SpydrBlade™ Flex device, allowing it to launch the product in the U.S. market.
CREO
NEUTRALCreo Medical Group Director Increases Shareholding
The healthcare company has announced that its Non-Executive Chairman has purchased additional shares in the business.
CREO
NEUTRALCreo Medical Group Publishes 2024 Annual Report and Announces AGM
The medical device company has published its 2024 Annual Report and Accounts and announced the date of its upcoming Annual General Meeting.
CREO
GOODCreo Medical Secures US Reimbursement for Speedboat Procedure
The medical device company has secured new reimbursement codes in the US for its Speedboat endoscopic procedure, a significant regulatory milestone that will help drive adoption of this advanced, minimally invasive treatment.
CREO
NEUTRALCreo Medical Group Announces Holding Change
The healthcare company has announced a change in its major shareholding structure.
CREO
NEUTRALCreo Medical Group Announces Holding Change
The healthcare company has announced a change in its major shareholding, with M&G Plc now holding over 10% of the voting rights.
CREO
NEUTRALCreo Medical Announces Directorate Changes
The medical device company announces changes to its board of directors, including the retirement of a non-executive director and some committee role changes.
CREO
NEUTRALCreo Medical Reports Strong Core Technology Growth Amid Increased Losses
The medical device company reported a 74% increase in Core Technology sales, but faced widening losses and margin pressure. A strategic sale strengthened its balance sheet amid ongoing economic uncertainties.